US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
INmune Bio Inc (INMB)
INmune Bio Inc (INMB) ニュース

INmune Bio Inc (INMB)

1.68

0.05

(3.07%)

終了 7月2日 5:00AM

1.6696

-0.0104

( -0.62% )

プレマーケット: 7:11PM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

Form 8-K - Current report

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program...

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for...

Form 8-K - Current report

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC...

Form 8-K - Current report

Form 8-K - Current report

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Canada NewsWire SAN FRANCISCO, May...

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage...

Form 8-K - Current report

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology...

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

81vette

81vette 7日前

https://investorshub.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/98808296/inmune-bio-inc-achieves-mhra-approval-of-pip-for

81vette

81vette 7日前

https://investorshub.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/trades

jondoeuk

jondoeuk 6月前

It failed in the first trial https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171636087 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174142836

It failed in the second trial https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175902173 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176527055

They now talk about a phase two expansion trial in solid tumours with residual disease.

AKsuited

AKsuited 7月前

Wen $10?
GL here

tw0122

jondoeuk

jondoeuk 11月前

From the wording of the press release, it seems there was (at least some) activity, but not enough to translate into any CRs or PRs https://finance.yahoo.com/news/inmune-bio-care-pc-trial-120000411.html

jondoeuk

jondoeuk 1年前

The trial missed its primary endpoint. The trial also missed its secondary endpoints. I doubt they will find a partner to advance it.

tredenwater2

tredenwater2 1年前

Perhaps INMB wojld have benefitted from using the FDA’s open label adaptive ph 2 cross over trial like Anavex did. We are clearly on a firm foundation of efficacy because if the ph 2a as we near approval in the EU.

On a financing note, yes I also highly appreciate Dr. Missling’s clear savvy moves to minimally allow dilution to Anavex shareholders on the way to approval…..inhouse!

Management of INMB should be ashamed for securing a financing deal ahead of releasing bad news. Did the funding source know the data and shorted against the box? Smells very bad!

tschussmann1

tschussmann1 1年前

Every Alzheimer's trial fail makes me appreciate AVXL that much more...

tschussmann1

tschussmann1 1年前

Yes indeed! Fortunately it was a small stake...not much effect on the portfolio.

retireat40

retireat40 1年前

Looks like a terrible decision

tschussmann1

tschussmann1 1年前

The low 5's after the 20% share increase priced at 6.30 provided a nice entry point...and not long to wait to see it it was a good decision.

murocman

murocman 1年前

Happens all the time. Not a surprise.

retireat40

retireat40 1年前

retireat40

retireat40 1年前

Then they dropped an offering at $6.30. What a shit move.

rbl100

OFFERING - @ $6.30 per share.....

tw0122

GhosTraderX

GhosTraderX 1年前

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
https://ih.advfn.com/stock-market/NASDAQ/inmune-bio-INMB/stock-news/96320079/inmune-bio-inc-to-announce-top-line-results-from
GhosT

jondoeuk

jondoeuk 1年前

An update https://www.globenewswire.com/news-release/2025/06/02/3091859/0/en/Syncromune-Inc-Presents-Positive-Results-from-SYNC-T-Therapy-SV-102-Phase-1-Metastatic-Prostate-Cancer-Trial-at-ASCO-2025.html

https://www.globenewswire.com/news-release/2025/05/30/3091053/0/en/Syncromune-Announces-First-Patient-Dosed-in-LEGION-100-Phase-2a-Trial-of-SYNC-T-Therapy-SV-102-for-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer.html

jondoeuk

jondoeuk 1年前

Apples to oranges, but this is the kind of data you want to see https://syncromune.com/wp-content/uploads/2024/04/SYNC-T-AACR-Website.pdf

jondoeuk

jondoeuk 1年前

So no scans, waterfall or swimmer plots! Doesn't look like there is any single-agent activity https://archive.fast-edgar.com/20250304/AD29K22CLM22K282222G22Y2M9BIZ2224272/ea023314201ex99-1_inmune.htm

Drugs with no single-agent activity rarely, if ever improve outcomes in randomised and controlled trials when used alone or in combination.

MartinLutherKing

MartinLutherKing 2年前

ELAB Partnership

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

INMB new 52 week low

tw0122

Study Demonstrate XPro converts microglia from a demyelinating cell to a remyelinating cell.Multi-year study published has implications for many CNS diseases including Alzheimer's.

tw0122

INMB 5.27 something brewing over here in some

Monksdream

Monksdream 2年前

INMB new 52 week low

Monksdream

Monksdream 2年前

jondoeuk

jondoeuk 2年前

''The third patient for the INKmune™ AML program in UK and EU has been enrolled and subsequent to their completion of follow-up, the company will wind down the AML program to focus resources on the prostate-cancer program and other solid tumors.'' https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html

Good luck to them in solid tumours!

Monksdream

Monksdream 2年前

INMB indeed it did

DollarDan

DollarDan 3年前

Starting to move up!

jondoeuk

jondoeuk 3年前

Did the trial in ovarian ever start?

derkampfer

derkampfer 3年前

Don't need to convince us. We are fully invested and believers in both the INKmune NK cell therapy for certain cancers as well as XPro for AD and possibly others neuro inflammation sensitive diseases, including Parkinson’s.

Two robust programs and each have multi-billion value potential based on TAM

Exciting times.

GLTA longs

jondoeuk

jondoeuk 3年前

Sure, it is early days in patients, but the data has yet to be https://ashpublications.org/blood/article/140/Supplement%201/4590/492304/In-Vivo-Generation-of-Memory-like-NK-Cells-for-the

Keep in mind that the ORR (focusing on R/R AML) is ~30-35% across multiple trials using adoptive transfer of non-engineered NK cells.

dennisdave

dennisdave 4年前

conix

INMB chart....finally a reversal?

conix

derkampfer

derkampfer 5年前

XPro news also impressive. Data very.

“The data from this Phase I trial show that XPro decreases biomarkers of neuroinflammation and nerve cell death while improving biomarkers of neurorepair in patients with AD,” stated RJ Tesi, M.D., CEO of INmune Bio

derkampfer

derkampfer 5年前

INKmune news was impressive. Albeit one patient dosed additional eight (8) in line. No toxicity. Ovarian cancer on deck.

https://finance.yahoo.com/news/inmune-bio-inc-announces-biomarker-200000970.html

spartex

spartex 5年前

Almost, $13 to $10 is a downward slope. but maybe over time things will be reversed??

spartex

spartex 5年前

Booooooom? More like, BurP! LOL. Still researching INMB

derkampfer

derkampfer 5年前

New run began today. Deeper dive Alzheimer’s drug they’re developing is phenomenal. Early studies some patients seeing reversed effects.

Unbelievable.

Fress

$INMB just ran from $2.00 to 30.00 congrats to the longs. what a beast of a stock.

*INmune Bio shares are trading higher after the company announced results for its Phase 1B study of XPro1595. The results show a decrease in biomarkers of neuroinflammation across multiple measures and assays, including cerebrospinal fluid and MRI.

$PDSB CD8+ (killer) T-cells. T cell platform is next.

$INMB

john sezso

john sezso 5年前

I need a bigger rake to scoop up all this cash trade....

john sezso

john sezso 5年前

Still crickets here....

john sezso

john sezso 5年前

Good enough for Harry Reid it's good enough for me. I'm in for the 50's

byrdiesoccer

byrdiesoccer 6年前

They are speaking with Roth Capital right now

akamaii

akamaii 6年前

Shorts bring this to 8 I wanna buy

l2 hunter

l2 hunter 6年前

INMB CHART >>>> going in position before test $25 next days again. after $25 blue skies... $13-$15 range a gift imho think will run big next days

starkd748

starkd748 6年前

Wow that public offering is peanuts ...Kaboom here tomorrow

Salazar Resources

Lazard Global Compounder...

HSBC MSCI AC FAR EAST ex...

S&P 500 Index ETF CAD He...

China Zhong Qi (EM)

Trinidad and Tobago Doll...

Domika Kritis R

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。